Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neogene
- Development stage
- Unknown
- Lead developer
- Anglo-French Drugs & Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Neogene (also known as Neogene Suspension) is an oral gastrointestinal suspension developed and marketed by Anglo-French Drugs & Industries. It is formulated as a sugar-free, mint-flavored liquid suspension designed to provide rapid relief from gastric hyperacidity and gas-related symptoms. Neogene is indicated for the management of esophagitis, epigastric pain, flatulence, peptic ulcers, and postoperative gas pain. Although its exact active ingredients are not publicly disclosed by the developer, it functions as an antacid and antiflatulent, offering a fast onset of action and high acid-neutralizing capacity to alleviate gastrointestinal discomfort.
- Brand names
- Neogene
- Other names
- Neogene Suspension
Beyond the preview
Go deeper on Neogene.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neogene.